(MedPage Today) — The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III trial showed.
Among 1,152 participants, average percentage of body…

Friday, October 2 – (MedPage Today) — Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails), compared with patients not taking the drugs, a large prospective…

Friday, October 2 – More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

Friday, October 2 – (MedPage Today) — An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern.
Participants taking 3.6 mg and 6…

Friday, October 2 – (MedPage Today) — Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed.
The percentage of women who initiated a GLP-1 medication within 6 months of delivery rose more than 20-fold, from…

Friday, October 2 – (MedPage Today) — In upstate New York, a nurse was choked with a stethoscope by a patient in the emergency room, according to police. (Syracuse.com)
A family is seeking answers after a patient fell to his death from a sixth floor window of a…

Thursday, October 1 – “Intervening in childhood could save children from decades of irreversible damage,” a transplant surgeon writes of GLP-1 weight loss drugs.

Thursday, October 1 – The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women’s Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women. The authors, that include Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK and colleagues, issue a call to action to improve the evidence based across the board for GLP-1 RA use in women worldwide.

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

Thursday, October 1 – Nail detachment is more than four times as common among people taking GLP-1 receptor agonists as among comparable people with obesity or type 2 diabetes who are not taking the drugs, according to the first controlled study to examine their potential effects on nail health.

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that negatively regulates muscle mass, can reduce lean mass loss during semaglutide treatment by 50% compared with semaglutide and placebo.

Thursday, October 1 – (MedPage Today) — Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven.
Among adults with type 2 diabetes and obesity or overweight at risk for increased cardiovascular…

Thursday, October 1 – Federal prosecutors have charged two people in an alleged scheme to bring fake versions of the type 2 diabetes drug Ozempic from China and sell them to U.S. distributors.

Thursday, October 1 – (MedPage Today) — Use of GLP-1 receptor agonists around pregnancy did not appear to increase adverse maternal or perinatal outcomes, according to two studies.
In a systematic review and meta-analysis of 10 studies representing over 2.1 million…

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight—generally less weight loss than with existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

Thursday, October 1 – Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the University of Georgia suggests patients aren’t taking the weight loss medication as prescribed, often because of high out-of-pocket costs.

Thursday, October 1 – EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and type 2 diabetes, setting up the launch of a Phase 3 trial before the end of the year.

Thursday, October 1 – An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.

Thursday, October 1 – New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Obstetrics, Gynaecology & Women’s Health shows that the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases. The findings are based on a review and meta-analysis of available studies.

Thursday, October 1 – Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.

Thursday, October 1 – New trial data for the weight loss drug called retatrutide shows it helped people living with obesity and type 2 diabetes lose up to 50lbs or 21% of their body weight. Those without diabetes lost up to 70lbs, 25% of body weight, making it the most weight loss ever recorded in a drug trial for diabetes patients. NBC medical contributor Dr. Natalie Azar joins TODAY to break down how the drug compares to GLP-1s.

Wednesday, September 30 – (MedPage Today) — GLP-1s and Stroke

Wednesday, September 30 – (MedPage Today) — The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets) as Class I, its most serious classification. (USA Today)
At least six major U.S. hospitals have shut down…

Tuesday, September 29 – New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.

Tuesday, September 29 – The number of people using GLP-1 treatments like Ozempic and Wegovy for weight loss or chronic conditions has increased rapidly, with more than 1 in 10 U.S. adults currently taking such medications. A new study led by medical students at Virginia Commonwealth University has shed light on how this rise in GLP-1 drug use is affecting Americans’ wallets.

Tuesday, September 29 – Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

Tuesday, September 29 – Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

Monday, September 28 – New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) to millions more people to protect their heart health.

Monday, September 28 – Experts share what you need to know about GLP-1-related hair loss as the side-effect gets more attention from researchers About 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic or Mounjaro are common brands) for weight loss and type 2 diabetes. As their use has surged, we’re learning more about their side-effects. One that’s been getting a lot of attention from researchers lately: hair loss.In one survey of people who take these medications, 20% of respondents experienced hair shedding, although the lack of high-quality data from a randomized, controlled trial to assess this side-effect makes it difficult to know exactly how common it is. Continue reading…

Sunday, September 27 – New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.

Sunday, September 27 – Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.

Saturday, September 26 – Chipotle, McDonald’s and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs.

Saturday, September 26 – Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a reported 5-year survival rate of approximately 13.3%, largely because of late diagnosis, rapid progression and resistance to treatment. GAIP-interacting protein C terminus 1 (GIPC1), overexpressed in PDAC, is a scaffolding protein that stabilizes multiple oncogenic receptors and signaling complexes involved in proliferation, survival, adhesion, migration and chemoresistance.

Friday, September 25 – Mylan Pharmaceuticals Inc. has launched a lawsuit in Delaware federal court asking for a finding that its proposed generic version of Novo Nordisk Inc.’s blockbuster weight loss drug Wegovy does not infringe a patent, the latest salvo in a larger intellectual property fight over the GLP-1.

Friday, September 25 – FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”

Friday, September 25 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor.

Friday, September 25 – Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.

Thursday, September 24 – Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal suggests that this effect cannot be entirely explained by patients losing weight on the drug.

Thursday, September 24 – (MedPage Today) — The FDA issued a warning letter this month to Empower Pharmacy over its mass production of compounded GLP-1 weight-loss and diabetes drugs, citing illegal copycat manufacturing and insanitary conditions.
Following a facility…

Thursday, September 24 – Woman who used semaglutide and lost vision is among people suing the makers of GLP-1 weight-loss drugs for not being warned about potential vision loss.